In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally ...

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...

Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is the ...

Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Robert F. Kennedy’s position on vaccines is profoundly "anti-science" and making progress would require a new health secretary, Pfizer Chief Executive Albert Bourla said Wednesday. “I have very ...

Albert Bourla, CEO of Pfizer, joins 'Money Movers' to discuss drug pricing, the impact on artificial intelligence on ...

Pfizer Inc. (NYSE:PFE) is included among Dividend Contenders List: Top 20 Stocks. Reuters reported on January 20 that Britain ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon. Even so, Lilly could carve out a niche ...

Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...